Search Results - (Author, Cooperation:D. Franchimont)

Showing 1 - 2 results of 2, query time: 0.14s Refine Results
  1. 1
    L. Jostins ; S. Ripke ; R. K. Weersma ; R. H. Duerr ; D. P. McGovern ; K. Y. Hui ; J. C. Lee ; L. P. Schumm ; Y. Sharma ; C. A. Anderson ; J. Essers ; M. Mitrovic ; K. Ning ; I. Cleynen ; E. Theatre ; S. L. Spain ; S. Raychaudhuri ; P. Goyette ; Z. Wei ; C. Abraham ; J. P. Achkar ; T. Ahmad ; L. Amininejad ; A. N. Ananthakrishnan ; V. Andersen ; J. M. Andrews ; L. Baidoo ; T. Balschun ; P. A. Bampton ; A. Bitton ; G. Boucher ; S. Brand ; C. Buning ; A. Cohain ; S. Cichon ; M. D'Amato ; D. De Jong ; K. L. Devaney ; M. Dubinsky ; C. Edwards ; D. Ellinghaus ; L. R. Ferguson ; D. Franchimont ; K. Fransen ; R. Gearry ; M. Georges ; C. Gieger ; J. Glas ; T. Haritunians ; A. Hart ; C. Hawkey ; M. Hedl ; X. Hu ; T. H. Karlsen ; L. Kupcinskas ; S. Kugathasan ; A. Latiano ; D. Laukens ; I. C. Lawrance ; C. W. Lees ; E. Louis ; G. Mahy ; J. Mansfield ; A. R. Morgan ; C. Mowat ; W. Newman ; O. Palmieri ; C. Y. Ponsioen ; U. Potocnik ; N. J. Prescott ; M. Regueiro ; J. I. Rotter ; R. K. Russell ; J. D. Sanderson ; M. Sans ; J. Satsangi ; S. Schreiber ; L. A. Simms ; J. Sventoraityte ; S. R. Targan ; K. D. Taylor ; M. Tremelling ; H. W. Verspaget ; M. De Vos ; C. Wijmenga ; D. C. Wilson ; J. Winkelmann ; R. J. Xavier ; S. Zeissig ; B. Zhang ; C. K. Zhang ; H. Zhao ; M. S. Silverberg ; V. Annese ; H. Hakonarson ; S. R. Brant ; G. Radford-Smith ; C. G. Mathew ; J. D. Rioux ; E. E. Schadt ; M. J. Daly ; A. Franke ; M. Parkes ; S. Vermeire ; J. C. Barrett ; J. H. Cho
    Nature Publishing Group (NPG)
    Published 2012
    Staff View
    Publication Date:
    2012-11-07
    Publisher:
    Nature Publishing Group (NPG)
    Print ISSN:
    0028-0836
    Electronic ISSN:
    1476-4687
    Topics:
    Biology
    Chemistry and Pharmacology
    Medicine
    Natural Sciences in General
    Physics
    Keywords:
    Colitis, Ulcerative/genetics/immunology/microbiology/physiopathology ; Crohn Disease/genetics/immunology/microbiology/physiopathology ; Genetic Predisposition to Disease/*genetics ; Genome, Human/genetics ; *Genome-Wide Association Study ; Haplotypes/genetics ; *Host-Pathogen Interactions/genetics/immunology ; Humans ; Inflammatory Bowel Diseases/*genetics/immunology/*microbiology/physiopathology ; Mycobacterium/*immunology/pathogenicity ; Mycobacterium Infections/genetics/microbiology ; Mycobacterium tuberculosis/immunology/pathogenicity ; Phenotype ; Polymorphism, Single Nucleotide/genetics ; Reproducibility of Results
    Published by:
    http://www.nature.com/

    Latest Papers from Table of Contents or Articles in Press
  2. 2
    Staff View
    ISSN:
    1365-2036
    Source:
    Blackwell Publishing Journal Backfiles 1879-2005
    Topics:
    Medicine
    Notes:
    Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1111/j.1365-2036.2004.02152.x

    Articles: DFG German National Licenses